Add 2 More Reports For 20% off

Report Overview

2024

Base Year

2018-2024

Historical Year

2025-2034

Forecast Year

Global Adalimumab Biosimilar Market Outlook

The global adalimumab biosimilar market is expected to grow at a CAGR of about 17.60% in the forecast period of 2025-2034, driven by the rising incidence of rheumatoid arthritis, especially amongst the rapidly growing geriatric population.

Global Adalimumab Biosimilar Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America, Asia Pacific, and Europe to be the Significant Regional Markets for Adalimumab Biosimilar

North America is expected to be one of the largest markets, owing to numerous large-scale testing laboratories worldwide. The rising incidence of rheumatoid arthritis and the growing geriatric population are among the major factors which are fuelling the market expansion in North America.

Due to extensive commercial advancements and growing biotechnology corporations in the province, Asia Pacific is anticipated to register sturdy growth over the projection period. The increasing focus to develop generic and biosimilar products in the emerging nations of Asia Pacific is estimated to fuel the global adalimumab biosimilar industry in the region.

Europe is expected to grow faster due to the rise in approvals of the new biosimilars, the ageing population, and increasing investments in the research and development of the new adalimumab biosimilars. For instance, in October 2018, Amgen Inc. launched AMGEVITA, a biosimilar of adalimumab.

Adalimumab Biosimilar: Market Segmentation

Adalimumab is a monoclonal antibody used to treat autoimmune illnesses, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and others. It accomplishes this by blocking Tumour Necrosis Factor (TNF), a soluble inflammatory cytokine. This drug helps prevent further joint injury and preserve joint function by lowering joint swelling.

Global Adalimumab Biosimilar Market by Segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By product, the market includes:

  • Exemptia
  • Adalirel
  • Cipleumab
  • Others

The several distribution channels of the market are:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

The regional markets for the adalimumab biosimilar industry can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

Global Adalimumab Biosimilar Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The Proliferation of Skin Disorders Augmenting the Market Growth

The most frequent illnesses that harm human health are skin disorders. Many skin disorders lead to lifelong disfigurement, stigma, and disability, and treating them effectively has become a significant concern for health organizations. In this context, a biosimilar of adalimumab has emerged as a feasible therapy option for persistent skin conditions like eczema. This aspect can significantly increase the size of the global adalimumab biosimilar industry throughout the forecast period. The multiple advantages, especially in treating psoriasis, adalimumab biosimilar is a preferred option for tackling skin disorders. The rising geriatric population and increasing public and private investment in pharmaceuticals will propel the market growth. Regulatory approvals for novel products motivate other companies to invest more in research and development and produce new inventions. Some global adalimumab biosimilar industry competitors are already working on new product development and portfolio expansion. For example, through a licencing deal with Cadila Healthcare, Glenmark Pharmaceuticals introduced ADALY, its adalimumab biosimilar medicine, in Mumbai in January 2018.

Key Industry Players in the Global Adalimumab Biosimilar Market

The report gives a detailed analysis of the following key players in the global adalimumab biosimilar industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Alfred E. Tiefenbacher (GmbH & Co. KG)
  • Amgen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Cadila Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Reliance Life Sciences Private Limited
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2018-2024
Forecast Period 2025-2034
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Distribution Channel
  • Region
Breakup by Product
  • Exemptia
  • Adalirel
  • Cipleumab
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Alfred E. Tiefenbacher (GmbH & Co. KG)
  • Amgen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Cadila Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Reliance Life Sciences Private Limited
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

Adalimumab Biosimilar Market Report Snapshots

Adalimumab Biosimilar Market Size

Adalimumab Biosimilar Market Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market is projected to grow at a CAGR of 17.60% between 2025 and 2034.

The major drivers of the market include the presence of numerous large-scale testing laboratories, rising incidence of rheumatoid arthritis, growing biotechnology corporations, increasing focus to develop generic and biosimilar products, rise in approvals of the new biosimilars, and growing investments in the research and development of the new adalimumab biosimilars.

The growing geriatric population and proliferation of skin disorders are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The different products are exemptia, adalirel, and cipleumab, among others.

The several distribution channels in the global adalimumab biosimilar market are hospital pharmacies and retail pharmacies, among others.

The major players in the industry are Alfred E. Tiefenbacher (GmbH & Co. KG), Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and Reliance Life Sciences Private Limited, among others.

Datasheet

10 % Off

USD

3,299

2,969

Single User License

10 % Off

USD

5,499

4,949

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 5,499

USD 4,949

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Selected Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Selected Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124